Loading
NASDAQHealthcareBiotechnology
Latest quote
$83.98
+$0.20 · +0.24%
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Latest quote
$83.98
+$0.20 · +0.24%
After-hours
$83.98
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Day range
Current $83.98
52-week range
Current $83.98
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
63
Bullish
Risk
47
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Day range
Current $83.98
52-week range
Current $83.98
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 9.9B USD | 13.01M USD | 5.6M USD | 7.59M USD | 6.49M USD |
| Selling, general, and administrative | 6.8B USD | 3.16M USD | 3.23M USD | 2.95M USD | 2.63M USD |
| Operating expenses | 16.7M USD | 16.16M USD | 8.83M USD | 10.54M USD | 9.13M USD |
| Interest income | 2.99M USD | 404.02K USD | 429.04K USD | 21.24K USD | 24.02K USD |
| Operating income | −16.7M USD | −16.16M USD | −8.83M USD | −10.54M USD | −9.13M USD |
| Net income | −13.72M USD | −15.59M USD | −8.4M USD | −10.52M USD | −9.1M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$126
50.04% upsidePrice history unavailable
High $145Average $126Low $105| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 13, 2024 | 1:5 | — | — |
Effective Aug 13, 2024
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI17.88M0.00%2.3T USD0.03%$379.56-0.39%
State Street SPDR S&P Biotech ETFXBI11.82M0.12%10.08B USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM10.16M0.01%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF5.11M0.01%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO2.9M0.02%18B USD0.06%$112.1-0.10%
Vanguard U.S. Momentum Factor ETFVFMO1.7M0.08%1.9B USD0.13%$227.78-0.44%
iShares Micro-Cap ETFIWC1.18M0.09%1.32B USD0.60%$182.79-0.31%
iShares Russell 2000 Growth ETFIWO884.38K0.01%14.04B USD0.24%$353.47-0.53%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOVanguard U.S. Momentum Factor ETFVFMOiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
